Therapeutic potential of selective estrogen receptor modulators

被引:81
|
作者
Gustafsson, JA [1 ]
机构
[1] Karolinska Inst, Novum, Dept Med Nutr, S-14186 Huddinge, Sweden
关键词
D O I
10.1016/S1367-5931(98)80127-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The hormone estradiol has effects on many tissues in both males and females. Some of these effects, such as inhibition of cancer growth and modulation of the devastating effects of aging on bone, brain, skin and bladder. are good. Others, such as the effects on the breast and endometrium, are undesirable. The task of designing drugs that would have only the good effects of estradiol has, until recently, seemed almost impossible because it was thought that there was only one estrogen receptor and that an estrogenic agent was definitively categorized as an estrogen agonist or an antagonist. More recently we have learnt that there are two estrogen receptors which, under certain conditions, have opposite effects on gene transcription. In addition, it is now understood that agents cannot be described as agonists or antagonists because a single agent can be an agonist in one tissue and an antagonist in another. The term 'selective estrogen receptor modulator' was designed to incorporate this. The idea of estrogen receptor modulators has raised new hope that tissue-specific estrogens or anti-estrogens can be designed.
引用
收藏
页码:508 / 511
页数:4
相关论文
共 50 条
  • [21] Potential of Selective Estrogen Receptor Modulators as Treatments and Preventives of Breast Cancer
    Peng, Jing
    Sengupta, Surojeet
    Jordan, V. Craig
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (05) : 481 - 499
  • [22] Selective estrogen receptor modulators: Tissue actions and potential for CNS protection
    Littleton-Kearney, MT
    Ostrowski, NL
    Cox, DA
    Rossberg, MI
    Hurn, PD
    CNS DRUG REVIEWS, 2002, 8 (03): : 309 - 330
  • [23] Preclinical Evidence for Therapeutic Efficacy of Selective Estrogen Receptor Modulators for Uterine Leiomyoma
    Cheryl Lyn Walker
    Kevin D. Burroughs
    Barbara Davis
    Kalyn Sowell
    Jeffrey I. Everitt
    Robin Fuchs-Young
    The Journal of the Society for Gynecologic Investigation: JSGI, 2000, 7 (4): : 249 - 256
  • [24] Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma
    Walker, CL
    Burroughs, KD
    Davis, B
    Sowell, K
    Everitt, JI
    Fuchs-Young, R
    JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION, 2000, 7 (04) : 249 - 256
  • [25] Selective Estrogen Receptor Modulators in COVID-19: A Possible Therapeutic Option?
    Calderone, Alba
    Menichetti, Francesco
    Santini, Ferruccio
    Colangelo, Luciano
    Lucenteforte, Ersilia
    Calderone, Vincenzo
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [26] Estrogen and Estrogen Receptor Modulators: Potential Therapeutic Strategies for COVID-19 and Breast Cancer
    Hu, Shuying
    Yin, Feiying
    Nie, Litao
    Wang, Yuqin
    Qin, Jian
    Chen, Jian
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [27] Selective estrogen receptor modulators and estrogen receptor α and β in breast cancer cells
    Power, KA
    Thompson, L
    FASEB JOURNAL, 2002, 16 (05): : A1003 - A1003
  • [28] Synthesis and estrogen binding activity of substituted naphthalenes: Potential selective estrogen receptor modulators (SERMS).
    Akwabi-Ameyaw, A
    Fang, J
    Heyer, D
    Katamreddy, SR
    Miller, AB
    Peckham, JP
    Navas, F
    Orband-Miller, LA
    Gray, D
    Shearin, J
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U961 - U961
  • [29] Effects of estrogen and selective estrogen receptor modulators on hemostasis and inflammation - Potential differences among drugs
    Cushman, M
    SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS), 2001, 949 : 175 - 180
  • [30] Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators
    Pinkerton, J. V.
    Conner, E. A.
    CLIMACTERIC, 2019, 22 (02) : 140 - 147